New methods improve skin disease diagnosis and treatment.
January 2025 in “Journal of Skin and Stem Cell” Gout can cause hair loss, but treatment can lead to hair regrowth.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
January 2025 in “RSC Pharmaceutics” Smart microneedles using advanced tech could improve psoriasis treatment.
January 2025 in “Advances in Dermatology and Allergology” Hair disorders in organ transplant patients are often underestimated and need more attention and research.
January 2025 in “Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)” An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.
December 2024 in “Journal of Population Therapeutics and Clinical Pharmacology” Psoriasis worsens in winter in India due to less sunlight and dry skin, needing personalized treatment.
December 2024 in “Mağallaẗ ʻulūm al-rāfidayn” Adding more zinc oxide nanoparticles increases sunblock SPF.
October 2024 in “Reumatizam” New treatments and understanding of skin lupus are emerging in 2024.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
September 2024 in “Portuguese Journal of Dermatology and Venereology” CCCA and LPP may be related hair loss conditions influenced by genetics and environment, needing early treatment.
Personalized, multidisciplinary care improves skin condition management and patient outcomes.
September 2024 in “Cermin Dunia Kedokteran” Fahr syndrome causes brain calcification and is managed by treating symptoms and underlying issues.
August 2024 in “Bioscience of Microbiota Food and Health” Microbes might play a role in vitiligo.
July 2024 in “International Journal of Medical Arts” Latanoprost is more effective than minoxidil for treating alopecia areata.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
May 2024 in “International Seven Journal of Multidisciplinary” More research is needed to better understand and treat Fibrosing Frontal Alopecia.
Baricitinib shows promise for treating alopecia areata with mild side effects.
Gender-specific analysis could improve treatment for childhood systemic lupus erythematosus.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
April 2024 in “Dermatology and therapy” There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
Onabotulinumtoxin-A effectively treated a painful scalp condition when other treatments failed.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
February 2024 in “Sohag Medical Journal” Various local treatments for alopecia areata show promise, but individualized plans and more research are needed.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
January 2024 in “Dermatology practical & conceptual” Atopic dermatitis in kids with alopecia areata can predict poor response to topical immunotherapy.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
December 2023 in “Intisari Sains Medis” SLE and DM can coexist but are rare and need careful evaluation.
December 2023 in “PubMed” Homemade skin products can cause allergic reactions, so use registered products if you have allergies.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.